Hepatic encephalopathy: cross-border specialty drug access for international patients

Quick orientation

Hepatic encephalopathy affects an estimated 30 to 45 percent of patients with cirrhosis at some point. Overt episodes are common in advanced liver disease.

Typical age of onset. Typically in adults with advanced chronic liver disease, but can occur in acute liver failure at any age.

Severity tiers. Severity is graded from minimal/covert to overt with confusion or coma. Recurrent episodes worsen prognosis.

Why specialty drugs for Hepatic encephalopathy are hard to access internationally

Standard therapies including lactulose and rifaximin are broadly available. Specialty options for refractory disease and acute liver failure are narrower internationally.

Treatments approved by the FDA

• Terlivaz (terlipressin) — FDA approval: 2022. Mechanism: Vasopressin V1 receptor agonist for hepatorenal syndrome (adjacent disease in advanced cirrhosis). Route: Intravenous bolus every 6 hours. US WAC ballpark: Approximately USD 30,000 to 90,000 per course. Country pricing: UAE · Saudi Arabia · India · Bahrain.
• Ravicti (glycerol phenylbutyrate) — FDA approval: 2013. Mechanism: Nitrogen-binding agent (urea cycle disorder label; sometimes used in hyperammonemia). Route: Oral with meals. US WAC ballpark: Approximately USD 300,000 to 800,000 per year. Country pricing: UAE · Saudi Arabia · India · Kuwait · Egypt · Jordan.

Cross-border pathways used for Hepatic encephalopathy

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Personal Import Scheme

What your physician needs to know

• Confirm precipitant of encephalopathy (infection, GI bleed, electrolyte disturbance, medication).
• Document liver disease etiology and MELD/Child-Pugh classification.
• Hepatology co-management for transplant candidacy is essential.
• Some products require hospital administration.
• Monitor renal function carefully during vasopressin analog use.

Common questions

Is Terlivaz the same as terlipressin used elsewhere?

Terlivaz is the US FDA-approved formulation of terlipressin. Other terlipressin formulations are used in many markets.

How long is the course?

Up to 14 days per label for hepatorenal syndrome type 1.

Can my patient receive at home?

Most acute encephalopathy and hepatorenal syndrome care occurs in hospital.

What documents are required?

Hepatologist's order, liver disease workup, and clinical summary.

Are there alternatives?

Standard care includes lactulose, rifaximin, and nutritional management. Specialty agents are reserved for specific clinical situations.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Hepatic encephalopathy, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Hepatic encephalopathy

Reserved for you.